Biotech Values

[DewDiligence]

HGSI – Agree with your post on all counts. Moreover, HGSI’s “preference share” market research supposedly showed that most of the sampled docs who thought q4w dosing was a big deal also thought q2w dosing was a big deal; hence, these docs will be on board in any case if q2w works out on safety, efficacy, and tolerability.